AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32474584 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term benzodiazepines
Number of subjects: 448
Study 32474584 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors without appropriate indication
Number of subjects: 448
Study 32474584 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton-Pump Inhibitors (PPIs) without appropriate indication
Number of subjects: 448
Study 32474584 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing number of PIMs
Number of subjects: 448
Study 32474584 — intervention group
Group type: EXPERIMENTAL
Intervention: PIM use
Number of subjects: 448
Study 35502947 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Cannabidiol (CBD)
Number of subjects: 12
Study 35502947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Cannabidiol (CBD)
Number of subjects: 12
Study 35502947 — intervention group
Group type: COMPARATOR
Intervention: Human studies of CBD
Number of subjects: 12
Study 34342172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 0.5 mg IV
Number of subjects: 8
Study 34342172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 1.25 mg IV
Number of subjects: 8
Study 34342172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg IV
Number of subjects: 8
Study 34342172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 3.75 mg IV
Number of subjects: 8
Study 34342172 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg IV
Number of subjects: 8
Study 34342172 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 5 mg oral
Number of subjects: 8
Study 34342172 — intervention group
Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 8
Study 34342172 — intervention group
Group type: COMPARATOR
Intervention: Placebo oral
Number of subjects: 8
Study 35839030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 81
Study 35839030 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNRB)
Number of subjects: 81
Study 35839030 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (NSAIDs)
Number of subjects: 81
Study 33232555 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (60 mg)
Number of subjects: 19
Study 33232555 — intervention group
Group type: COMPARATOR
Intervention: Placebo (glucose syrup)
Number of subjects: 19
Study 35925582 — intervention group
Group type: EXPERIMENTAL
Intervention: mVRBT‐MRc
Number of subjects: 25
Study 35925582 — intervention group
Group type: COMPARATOR
Intervention: aSRT‐MRc
Number of subjects: 25
Study 36270544 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (PT) + high-intensity interval training (HIIT)
Number of subjects: 35
Study 36270544 — intervention group
Group type: COMPARATOR
Intervention: Traditional strength training (TST) + high-intensity interval training (HIIT)
Number of subjects: 35
Study 36270544 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (PT) + HIIT
Number of subjects: 35
Study 36270544 — intervention group
Group type: COMPARATOR
Intervention: Traditional strength training (TST) + HIIT
Number of subjects: 35
Study 34916642 — intervention group
Group type: COMPARATOR
Intervention: Conventional brain-guided (free-hand) implant surgery
Number of subjects: 90
Study 34916642 — intervention group
Group type: COMPARATOR
Intervention: Dynamic computer-assisted implant surgery (dCAIS)
Number of subjects: 90
Study 34916642 — intervention group
Group type: COMPARATOR
Intervention: Static computer-assisted implant surgery (sCAIS)
Number of subjects: 90
Study 34916642 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 90
Study 34907003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy, ≥5 sessions (1 per day) for 90 minutes at 1.45 ATA for 7 days
Number of subjects: 40
Study 34907003 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for respiratory symptoms for 7 days
Number of subjects: 40
Study 34907003 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 40
Study 33443079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (25 mg, 4-weekly subcutaneous injections for 12 weeks)
Number of subjects: 20
Study 33443079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (25 mg)
Number of subjects: 20
Study 33443079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32464019 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 7
Study 32464019 — intervention group
Group type: COMPARATOR
Intervention: Blood clot alone (Control)
Number of subjects: 7
Study 33793377 — intervention group
Group type: EXPERIMENTAL
Intervention: Service attendance as a congregation-level variable
Number of subjects: 239
Study 33793377 — intervention group
Group type: COMPARATOR
Intervention: Service attendance
Number of subjects: 239
Study 34271274 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 164
Study 34271274 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 164
Study 35978306 — intervention group
Group type: EXPERIMENTAL
Intervention: ValueCare intervention (ICT-enabled value-based methodology for integrated care)
Number of subjects: 240
Study 35978306 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 240
Study 34063083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting and glucose administration paired with relaxation and guided imagery
Number of subjects: 32
Study 34063083 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 32
Study 32368355 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC and mEHT plus best supportive care (BSC)
Number of subjects: 97
Study 32368355 — intervention group
Group type: COMPARATOR
Intervention: BSC alone
Number of subjects: 97
Study 32368355 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC and mEHT plus BSC
Number of subjects: 97
Study 34855460 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-selected peripheral blood stem cell
Number of subjects: 346
Study 34855460 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCy after bone marrow graft
Number of subjects: 346
Study 34855460 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and methotrexate after bone marrow graft (control)
Number of subjects: 346
Study 32789011 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimised information materials
Number of subjects: 11531
Study 32789011 — intervention group
Group type: COMPARATOR
Intervention: Standard trial information
Number of subjects: 11531
Study 36054786 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaktinib 100 mg BID
Number of subjects: 118
Study 36054786 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaktinib 200 mg QD
Number of subjects: 118
Study 33217336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study 33614436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided serratus plane block (UGSPB)
Number of subjects: 4
Study 33614436 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methadone
Number of subjects: 4
Study 35880768 — intervention group
Group type: EXPERIMENTAL
Intervention: Fee-for-service payment
Number of subjects: 44
Study 35880768 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-performance incentives
Number of subjects: 44
Study 35880768 — intervention group
Group type: EXPERIMENTAL
Intervention: Grant funds
Number of subjects: 44
Study 35880768 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care Management billing (CPT) codes
Number of subjects: 44
Study 35880768 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service and pay-for-performance incentives
Number of subjects: 44
Study 35880768 — intervention group
Group type: COMPARATOR
Intervention: Grants and/or general medical education funds
Number of subjects: 44
Study 34171356 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveOne Gold (WOG) system
Number of subjects: 148
Study 34171356 — intervention group
Group type: COMPARATOR
Intervention: XP-endo Shaper (XPES) system
Number of subjects: 148
Study 34171356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WOG and XPES systems
Number of subjects: 148
Study 32001844 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn service readiness assessment
Number of subjects: 0
Study 32001844 — intervention group
Group type: EXPERIMENTAL
Intervention: General requirements, equipment, medicines and commodities, staffing and guidelines
Number of subjects: 0
Study 32001844 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of staff
Number of subjects: 0
Study 32001844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation and heater for room temperature maintenance
Number of subjects: 0
Study 32001844 — intervention group
Group type: EXPERIMENTAL
Intervention: Training coverage
Number of subjects: 0
Study 35182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg
Number of subjects: 80
Study 35182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg with simvastatin dosed 2 hours before, and 4 and 10 hours after
Number of subjects: 80
Study 35182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg with a statin
Number of subjects: 80
Study 35182045 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 200 mg with statins
Number of subjects: 80
Study 32398131 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated microfinance-group medical visit model for NCD, involving monthly group medical visits led by a community health educator and a rural clinician, tested over a 6-month pilot.
Number of subjects: 0
Study 34273181 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Patient and Public Involvement (PPI) in RCTs
Number of subjects: 0
Study 34273181 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation groups in RCTs
Number of subjects: 0
Study 34273181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages of trial process for PPI
Number of subjects: 0
Study 34273181 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods of collecting opinions
Number of subjects: 0
Study 32530172 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (eye tracking)
Number of subjects: 40
Study 32530172 — intervention group
Group type: COMPARATOR
Intervention: Control group (direct collection of eye movement parameters)
Number of subjects: 40
Study 33973398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Number of subjects: 50
Study 33973398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 50
Study 33973398 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care and Exercise therapy (combined)
Number of subjects: 50
Study 32875536 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable-based physical activity intervention (Garmin Vivofit2® with behavioral feedback, goal setting, and health coaching)
Number of subjects: 83
Study 32875536 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable-based physical activity intervention
Number of subjects: 83
Study 32875536 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 83
Study 34889150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical plexus block (CPB)
Number of subjects: 29
Study 34889150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical plexus block (CPB) with translaryngeal block (Group ST)
Number of subjects: 29
Study 35260464 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg two times a day)
Number of subjects: 20000
Study 35260464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR target 1.7-2.2)
Number of subjects: 20000
Study 35260464 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/day)
Number of subjects: 20000
Study 34750128 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching program
Number of subjects: 290
Study 32774189 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual compression for hemostasis
Number of subjects: 46
Study 34823375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (exact dosage and duration not specified)
Number of subjects: 133
Study 34823375 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF (EF ≥45%)
Number of subjects: 133
Study 35189811 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1072
Study 35189811 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1072
Study 35189811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1072
Study 35189811 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab (both doses)
Number of subjects: 1072
Study 34038904 — intervention group
Group type: EXPERIMENTAL
Intervention: Snail Soothing and Repairing (SSR) cream applied twice daily for 14 days
Number of subjects: 22
Study 34038904 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied twice daily for 14 days
Number of subjects: 22
Study 36484185 — intervention group
Group type: EXPERIMENTAL
Intervention: Navel acupuncture, 30 min each time, once every other day, for 4 weeks
Number of subjects: 106
Study 36484185 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (drugs, catheterization, bladder function rehabilitation training)
Number of subjects: 106
Study 34263648 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron total glycoside tablets (four tablets each time, three times each day for 6 months)
Number of subjects: 200
Study 34263648 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four tablets each time, three times each day for 6 months)
Number of subjects: 200
Study 34263648 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron total glycoside tablets
Number of subjects: 200
Study 34263648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 32648464 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 30
Study 32648464 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study 36220075 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Cycle
Number of subjects: 145
Study 36220075 — intervention group
Group type: COMPARATOR
Intervention: Modified Natural Cycle
Number of subjects: 145
Study 33010240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide 25 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Number of subjects: 1053
Study 33010240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg, and dolutegravir 50 mg
Number of subjects: 1053
Study 33010240 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, and efavirenz 600 mg
Number of subjects: 1053
Study 33010240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide, emtricitabine, and dolutegravir
Number of subjects: 1053
Study 33010240 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate, emtricitabine, and dolutegravir
Number of subjects: 1053
Study 33010240 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz
Number of subjects: 1053
Study 34213361 — intervention group
Group type: EXPERIMENTAL
Intervention: Statements attributed to a female scientist
Number of subjects: 0
Study 34213361 — intervention group
Group type: COMPARATOR
Intervention: Statements attributed to a male scientist
Number of subjects: 0
Study 36209235 — intervention group
Group type: EXPERIMENTAL
Intervention: WGS-guided automated treatment recommendation strategy for individualized treatment of RR-TB
Number of subjects: 0
Study 36209235 — intervention group
Group type: COMPARATOR
Intervention: RR-TB treatment according to the national South African guidelines
Number of subjects: 0
Study 34076381 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGF (plasma rich in growth factors)
Number of subjects: 43
Study 34076381 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF (platelet-rich fibrin)
Number of subjects: 43
Study 34076381 — intervention group
Group type: COMPARATOR
Intervention: Control (hemostatic sponge containing gentamicin)
Number of subjects: 43
Study 34958359 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 487
Study 34958359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 35966744 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion for harmonization of Yin and Yang
Number of subjects: 216
Study 35966744 — intervention group
Group type: COMPARATOR
Intervention: Gentle moxibustion
Number of subjects: 216
Study 32880493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) in addition to Transforaminal Epidural Steroid Injection (TFESI)
Number of subjects: 0
Study 32880493 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal Epidural Steroid Injection (TFESI) alone
Number of subjects: 0
Study 616768357 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 616768357 — intervention group
Group type: COMPARATOR
Intervention: No BCG vaccination (control)
Number of subjects: 0
Study 36048481 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT intervention (INT)
Number of subjects: 45
Study 36048481 — intervention group
Group type: COMPARATOR
Intervention: Regular PE (CON)
Number of subjects: 45
Study 33481506 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-rainbow
Number of subjects: 50
Study 33481506 — intervention group
Group type: COMPARATOR
Intervention: hot-metal new
Number of subjects: 50
Study 35147583 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with viral load >400 copies/mL
Number of subjects: 7720
Study 35147583 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 7720
Study 35147583 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian participants
Number of subjects: 7720
Study 35147583 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 7720
Study 34145009 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised rehabilitation programme with five additional therapy sessions (one during hospitalisation, four in the municipality, and a follow-up phone call)
Number of subjects: 14
Study 34145009 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised intervention component
Number of subjects: 14
Study 32627192 — intervention group
Group type: COMPARATOR
Intervention: Self‐Compassion for Healthcare Communities (SCHC) program
Number of subjects: 58
Study 33097204 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation with anterolateral plating, medial plating, or both
Number of subjects: 42
Study 33097204 — intervention group
Group type: COMPARATOR
Intervention: Dual column plating
Number of subjects: 42
Study 32410827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow-derived lineage-negative stem/progenitor cells (LIN- SPCs)
Number of subjects: 34
Study 32410827 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group)
Number of subjects: 34
Study 34385269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic assessment and management pathway
Number of subjects: 498
Study 34385269 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 498
Study 34496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bursted percutaneous auricular vagus nerve stimulation (pVNS)
Number of subjects: 9
Study 35353061 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc (RC) files with reciprocating motion
Number of subjects: 58
Study 35353061 — intervention group
Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive (TFA) system with adaptive motion
Number of subjects: 58
Study 33795174 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet
Number of subjects: 327
Study 33795174 — intervention group
Group type: COMPARATOR
Intervention: No Tourniquet
Number of subjects: 327
Study 32536335 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet Mind Training (QMT)
Number of subjects: 30
Study 32536335 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study 32068197 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led program of care
Number of subjects: 152
Study 32068197 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study 35632653 — intervention group
Group type: EXPERIMENTAL
Intervention: GamCOVIDVac vaccine
Number of subjects: 1000
Study 35632653 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiVacCorona vaccine
Number of subjects: 1000
Study 35632653 — intervention group
Group type: COMPARATOR
Intervention: No specific vaccine (prior to vaccination)
Number of subjects: 1000
Study 35632653 — intervention group
Group type: COMPARATOR
Intervention: Monitoring stages 1-3
Number of subjects: 1000
Study 35632653 — intervention group
Group type: COMPARATOR
Intervention: Monitoring stages 4-5
Number of subjects: 1000
Study 35632653 — intervention group
Group type: COMPARATOR
Intervention: Overall seropositivity
Number of subjects: 1000
Study 35632653 — intervention group
Group type: COMPARATOR
Intervention: Low anti-RBD Abs levels
Number of subjects: 1000
Study 35632653 — intervention group
Group type: COMPARATOR
Intervention: High Ab levels
Number of subjects: 1000
Study 33094519 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton swab sampling
Number of subjects: 205
Study 33094519 — intervention group
Group type: COMPARATOR
Intervention: Stained smears (microscopic examination)
Number of subjects: 205
Study 33422560 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclarix risk score
Number of subjects: 457
Study 33422560 — intervention group
Group type: COMPARATOR
Intervention: %free PSA (%fPSA)
Number of subjects: 457
Study 33422560 — intervention group
Group type: COMPARATOR
Intervention: European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculator (RC)
Number of subjects: 457
Study 33422560 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclarix density
Number of subjects: 457
Study 33422560 — intervention group
Group type: COMPARATOR
Intervention: PSA density
Number of subjects: 457
Study 34445995 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART model group (n=360)
Number of subjects: 840